
|Videos|October 10, 2016
An Overview of the AM0010 Study in Kidney Cancer, Other Cancers
Author(s)Jeffrey Infante, MD
Jeffrey Infante, MD, Director of Drug Development at Sarah Cannon, discusses findings of the AM0010 study.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































